Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Brendan Murphy Everett, M.D.

Co-Author

This page shows the publications co-authored by Brendan Everett and Peter Libby.
Connection Strength

2.026
  1. Novel Antiatherosclerotic Therapies. Arterioscler Thromb Vasc Biol. 2019 04; 39(4):538-545.
    View in: PubMed
    Score: 0.832
  2. Inhibition of Interleukin-1ß and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial. J Am Coll Cardiol. 2020 10 06; 76(14):1660-1670.
    View in: PubMed
    Score: 0.231
  3. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation. 2019 03 05; 139(10):1289-1299.
    View in: PubMed
    Score: 0.207
  4. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. J Am Coll Cardiol. 2018 05 29; 71(21):2392-2401.
    View in: PubMed
    Score: 0.193
  5. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013 Aug; 166(2):199-207.e15.
    View in: PubMed
    Score: 0.138
  6. Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019 02 21; 380(8):752-762.
    View in: PubMed
    Score: 0.051
  7. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018 10 07; 39(38):3499-3507.
    View in: PubMed
    Score: 0.050
  8. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018 12; 206:80-93.
    View in: PubMed
    Score: 0.050
  9. Relationship of Interleukin-1ß Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial. Ann Intern Med. 2018 10 16; 169(8):535-542.
    View in: PubMed
    Score: 0.050
  10. Inhibition of Interleukin-1ß by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease. J Am Coll Cardiol. 2018 05 29; 71(21):2405-2414.
    View in: PubMed
    Score: 0.049
  11. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018 01 27; 391(10118):319-328.
    View in: PubMed
    Score: 0.047
  12. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 09 21; 377(12):1119-1131.
    View in: PubMed
    Score: 0.047
  13. Effect of interleukin-1ß inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017 Oct 21; 390(10105):1833-1842.
    View in: PubMed
    Score: 0.047
  14. Effects of interleukin-1ß inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 2012 Dec 04; 126(23):2739-48.
    View in: PubMed
    Score: 0.033
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.